This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HTGM HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About HTG Molecular Diagnostics Stock (NASDAQ:HTGM) Get HTGM alerts:Sign Up Key Stats Today's Range N/A50-Day Range$5.01▼$6.8052-Week Range N/AVolume773,040 shsAverage Volume294,806 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ. Read More Receive HTGM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HTG Molecular Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HTGM Stock News HeadlinesHTGMQ HTG Molecular Diagnostics, Inc.March 30, 2024 | seekingalpha.comHTG Molecular Diagnostics Inc HTGMQJanuary 4, 2024 | morningstar.comMMy starkest warning in years Porter Stansberry — founder of one of the world’s largest financial research firms — believes we’re entering a historic economic shift he calls The Final Displacement. Backed by warnings from Nobel Prize winners, this rare event could reshape everything from markets to personal wealth, just as past global displacements toppled empires and created new fortunes. His new investigation reveals why it’s unfolding now, what’s driving it, and how to position yourself on the right side of history.October 26 at 2:00 AM | Porter & Company (Ad)HTG Molecular Diagnostics Inc (HTGMQ)September 26, 2023 | uk.investing.comMolecular Diagnostics Market Research Report 2023 Growth, Recent Trends and Forecast to 2028 by Key PlayersAugust 26, 2023 | benzinga.comHTG Molecular stock tanks in wake of Chapter 11 bankruptcy filingJune 6, 2023 | msn.comWhy Are HTG Molecular Diagnostics Shares Plunging TodayJune 6, 2023 | finance.yahoo.comWhy Is HTG Molecular Diagnostics (HTGM) Stock Down 42% Today?June 6, 2023 | investorplace.comSee More Headlines HTGM Stock Analysis - Frequently Asked Questions How were HTG Molecular Diagnostics' earnings last quarter? HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its quarterly earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) EPS for the quarter, meeting analysts' consensus estimates of ($0.60). The medical research company earned $2.52 million during the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a negative net margin of 324.25% and a positive trailing twelve-month return on equity of 45.52%. When did HTG Molecular Diagnostics IPO? HTG Molecular Diagnostics (HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers. What other stocks do shareholders of HTG Molecular Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that HTG Molecular Diagnostics investors own include Sangamo Therapeutics (SGMO), Idera Pharmaceuticals (IDRA), NightHawk Biosciences (NHWK), Abeona Therapeutics (ABEO), Exelixis (EXEL), Bionano Genomics (BNGO) and Adamis Pharmaceuticals (ADMP). Company Calendar Last Earnings11/10/2021Today10/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryN/A Current SymbolNASDAQ:HTGM CIK1169987 Webwww.htgmolecular.com Phone(520) 547-2827Fax520-547-2837Employees84Year Founded1997Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.59 million Net Margins-324.25% Pretax Margin-324.05% Return on Equity45.52% Return on Assets8.93% Debt Debt-to-Equity RatioN/A Current Ratio1.40 Quick Ratio1.30 Sales & Book Value Annual Sales$6.37 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.44 per share Price / BookN/AMiscellaneous Outstanding Shares2,210,000Free Float2,156,000Market CapN/A OptionableOptionable Beta0.99 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:HTGM) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredA Worldwide Gold Lockdown Is Now UnderwayCentral banks around the world are hoarding gold at one of the fastest rates in history — and former Goldman S...Stansberry Research | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?While headlines point to collapsing sales and fading tax credits, tech analyst Jeff Brown says Tesla is on the...Brownstone Research | SponsoredThis gold stock is STILL undervalued by 80%...“Like buying gold for $1,000/oz” If you could go back in time to 10+ years ago and buy gold for $1,000 an o...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HTG Molecular Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HTG Molecular Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
